Roche | News, Hiring, Layoffs, Competitors, CEO, Fundraising Insights
Roche is a global pioneer in pharmaceuticals and diagnostics, founded in 1896 in Basel, Switzerland. The company focuses on advancing...
Roche is a global pioneer in pharmaceuticals and diagnostics, founded in 1896 in Basel, Switzerland. The company focuses on advancing science to improve people's lives, with a strong emphasis on personalized healthcare. Roche is the world's largest biotech company, known for its innovative medicines in oncology, immunology, infectious diseases, and diagnostics. The company aims to improve patient access to medical innovations and has been recognized for its sustainability efforts in the pharmaceuticals and biotechnology industry.
Website
Size
10,001+ employees
Industry
Biotechnology Research
Specialities
biotechnology, innovation, personalized healthcare, great place to work, diagnostics, pharmaceuticals, research, healthcare, personalised healthcare, diabetes care, genomics, healthcare technology, big data, Science
ποΈ Roche Product and Pricing News β
π Roche CEO, Management and Leadership Team β
βοΈ Roche Alternatives and Competitors β
πΌ Roche Hiring and Layoffs β
π€ Roche Developer, Integration and Automation News β
π Roche Financials, Fundraising and Valuation News β
ποΈ Roche Product and Pricing News
- Roche Tissue Diagnostics developed the FDA-approved VENTANA FOLR1 RxDx assay for assessing folate receptor Ξ± expression in certain cancers.
- Delhi High Court has asked NATCO Pharma to pause the launch of Risdiplam due to a patent dispute with Roche.
- Belgian anti-trust authorities are investigating Roche for allegedly delaying biosimilars of two cancer medicines by offering financial incentives to hospitals and spreading misleading information.
- Roche is set to enter the pan-RAS inhibitor market with the first-in-human trial of RO7673396, starting April 30, 2025.
- On March 21, the FDA approved Roche's Susvimo as the first continuous treatment for diabetes-related blindness.
- Roche is suspending some global workforce diversity programs to avoid US sanctions.
- Roche announced its first FDA clearance using Real World Data, marking a significant advancement in diagnostic submissions and patient care.
- The FDA accepted Roche's Gazyva/Gazyvaro for lupus nephritis review after the phase III REGENCY trial showed significant improvement in complete renal response.
π Roche CEO, Management and Leadership Team
-
President & CEO, Roche Canada Pharmaceuticals
[email protected] -
Director de Estrategia de Soluciones y TransformaciΓ³n en Salud
-
CEO Roche Diagnostics[email protected]
-
Chief Technology Officer, Diagnostics[email protected]
-
Executive Director[email protected]
-
Chief Executive Officer[email protected]
-
President and CEO, Roche Diagnostics North America[email protected]
-
Commercial Director[email protected]
-
Technology Management Lead
-
CEO Roche Group[email protected]
-
President, Managing Director[email protected]
-
Chief Executive Officer[email protected]
-
CEO Genmark, a member of the Roche group[email protected]
βοΈ Roche Alternatives and Competitors
- Baxalta |
- Genentech |
- GSK |
- Pfizer |
- Bio-Rad Laboratories |
- Novartis |
- AstraZeneca |
- AbbVie |
- Merck |
- Novo Nordisk |
- MorphoSys |
- GENINUS |
- PIPA |
- Cipla |
- Bristol Myers Squibb |
- Johnson & Johnson |
- Lilly |
- Abbott |
- Medtronic |
- Amgen
πΌ Roche Hiring and Layoffs
- Roche is hiring a Chief of Staff for Global Safety, Health & Environment in Basel, Switzerland, to drive strategy and collaboration within their Corporate Strategy & Sustainability organization.
- On March 25, 2025, Roche re-elected Severin Schwan as Chairman of the Board and announced a 38th consecutive dividend increase to CHF 9.70 per share at its Annual General Meeting.
- Sameh Namangani has left Roche as Head of Supply Chain in Saudi Arabia to join Fakeeh Complementary as Chief Executive Officer.
- Roche is currently hiring for the position of Chief of Staff in Japan.
- Peter Vereckei Dr. has joined Roche as Country Medical Director in Hungary, previously holding a position at another company.
- Roche is currently seeking a Head of Innovation and Business Development in Serbia.
- Nicola Romanello has joined Roche as General Manager Pharma Chile in the Santiago Metropolitan Area, previously serving as Business Unit Director, Andean Cluster at Pfizer.
- Roche is currently hiring a Medical Affairs Partner, Neuroscience in Hong Kong.
π€ Roche Developer, Integration and Automation News
- On March 26, 2025, the University of Liverpool signed a Memorandum of Understanding with Roche Diagnostics UK and Ireland to advance research and innovation for health improvement and community prosperity.
- Roche has partnered with Merck KGaA to commercialize the lung cancer drug Tepmetko in mainland China.
- Roche UK partnered with Great Ormond Street Hospital to establish the Clinical Insights Unit, which has been shortlisted for two HSJ Digital Awards for its innovative use of data and analytics.
- Roche, represented by General Manager Deepti Saraf, launched the 'Empower HER' program in partnership with Sarawak Energy to fund breast cancer treatment for financially challenged patients in Sarawak.
- On March 19, 2025, Roche announced a multi-year collaboration with Oxford BioTherapeutics to develop antibody-based cancer treatments.
- Roche and Zealand Pharma signed a collaboration and licensing agreement to jointly develop and commercialize petrelintide for overweight and obese individuals, enhancing Roche's cardiovascular, renal, and metabolic disease portfolio.
- Roche Diagnostics is collaborating with the University of Liverpool to launch the Eye Cancer Artificial Intelligence Digital Bioresource (EYE-CAN-AID) using their VENTANA DP 600 pathology slide scanners to enhance early detection of rare eye cancers.
- Roche is collaborating with Recursion and Genentech on neuroscience and GI oncology projects.
π Roche Financials, Fundraising and Valuation News
- Roche invested $36 million in Puretech with potential milestone payments and royalties up to $1 billion.
- Roche and Zealand Pharma have signed a $5.3 billion agreement for treatment development.
- Roche acquired Poseida Therapeutics, indicating interest in allo CAR-T therapies.
- Roche is rumored to be planning a reverse merger with LumiraDx, similar to LumiraDx's previous merger with Covington Associates Healthcare.
- Roche grew by 9% in the last three quarters of 2024.
People also viewed
- Swiss Life |
- Grover |
- Pix4D |
- Purple |
- Saatva |
- Sleep Number
